Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

August 2020 | 121 pages | ID: A2244224F7BDEN
GMD Research

Abstracts

Asia Pacific antibiotics market will grow by 4.1% annually with a total addressable market cap of $253.1 billion over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Highlighted with 32 tables and 58 figures, this 121-page report “Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cephalosporin
• Penicillin
• Macrolides
• Fluoroquinolones
• Quinolones
• Monobactam
• Aminoglycosides
• Carbapenem
• Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Oral Administration
• Intravenous Administration
• Other Administration Routes

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY DRUG CLASS

3.1 Market Overview by Drug Class
3.2 Cephalosporin
3.3 Penicillin
3.4 Macrolides
3.5 Fluoroquinolones
3.6 Quinolones
3.7 Monobactam
3.8 Aminoglycosides
3.9 Carbapenem
3.10 Other Drug Classes

4 SEGMENTATION OF ASIA PACIFIC MARKET BY ACTION MECHANISM

4.1 Market Overview by Action Mechanism
4.2 Cell Wall Synthesis Inhibitors
4.3 Mycolic Acid Inhibitors
4.4 RNA Synthesis Inhibitors
4.5 DNA Synthesis Inhibitors
4.6 Protein Synthesis Inhibitors
4.7 Other Mechanisms

5 SEGMENTATION OF ASIA PACIFIC MARKET BY DRUG ORIGIN

5.1 Market Overview by Drug Origin
5.2 Natural Antibiotics
5.3 Semi-synthetic Antibiotics
5.4 Synthetic Antibiotics

6 SEGMENTATION OF ASIA PACIFIC MARKET BY ACTIVITY SPECTRUM

6.1 Market Overview by Activity Spectrum
6.2 Broad-spectrum Antibiotics
6.3 Narrow-spectrum Antibiotics

7 SEGMENTATION OF ASIA PACIFIC MARKET BY ROUTE OF ADMINISTRATION

7.1 Market Overview by Route of Administration
7.2 Oral Administration
7.3 Intravenous Administration
7.4 Other Administration Routes

8 SEGMENTATION OF ASIA PACIFIC MARKET BY DRUG TYPE

8.1 Market Overview by Drug Type
8.2 Brand Antibiotics
8.3 Generic Antibiotics

9 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY

9.1 Overview of Asia-Pacific Market
9.2 Japan
9.3 China
9.4 Australia
9.5 India
9.6 South Korea
9.7 Rest of APAC Region

10 COMPETITIVE LANDSCAPE

10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

11 INVESTING IN ASIA PACIFIC MARKET: RISK ASSESSMENT AND MANAGEMENT

11.1 Risk Evaluation of Asia Pacific Market
11.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Antibiotics Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Antibiotics Market
Table 3. Asia Pacific Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 4. Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, $ mn
Table 5. Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 6. Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, $ mn
Table 7. Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 8. Asia Pacific Antibiotics Market by Drug Type, 2019-2030, $ bn
Table 9. APAC Antibiotics Market by Country, 2019-2030, $ bn
Table 10. Japan Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 11. Japan Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 12. Japan Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 13. China Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 14. China Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 15. China Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 16. Australia Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 17. Australia Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 18. Australia Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 19. India Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 20. India Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 21. India Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 22. South Korea Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 23. South Korea Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 24. South Korea Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 25. Antibiotics Market in Rest of APAC by Country, 2019-2030, $ bn
Table 26. Abbott Laboratories: Company Snapshot
Table 27. Abbott Laboratories: Business Segmentation
Table 28. Abbott Laboratories: Product Portfolio
Table 29. Abbott Laboratories: Revenue, 2016-2018, $ mn
Table 30. Abbott Laboratories: Recent Developments
Table 31. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030
Table 32. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Asia Pacific Antibiotics Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Antibiotics Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Antibiotics Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Antibiotics Market
Figure 13. Breakdown of Asia Pacific Antibiotics Market by Drug Class, 2019-2030, % of Revenue
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)
Figure 15. Asia Pacific Antibiotics Market: Cephalosporin, 2019-2030, $ mn
Figure 16. Asia Pacific Antibiotics Market: Penicillin, 2019-2030, $ mn
Figure 17. Asia Pacific Antibiotics Market: Macrolides, 2019-2030, $ mn
Figure 18. Asia Pacific Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn
Figure 19. Asia Pacific Antibiotics Market: Quinolones, 2019-2030, $ mn
Figure 20. Asia Pacific Antibiotics Market: Monobactam, 2019-2030, $ mn
Figure 21. Asia Pacific Antibiotics Market: Aminoglycosides, 2019-2030, $ mn
Figure 22. Asia Pacific Antibiotics Market: Carbapenem, 2019-2030, $ mn
Figure 23. Asia Pacific Antibiotics Market: Other Drug Classes, 2019-2030, $ mn
Figure 24. Breakdown of Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue
Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)
Figure 26. Asia Pacific Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn
Figure 27. Asia Pacific Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn
Figure 28. Asia Pacific Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 29. Asia Pacific Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 30. Asia Pacific Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn
Figure 31. Asia Pacific Antibiotics Market: Other Mechanisms, 2019-2030, $ mn
Figure 32. Breakdown of Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue
Figure 33. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)
Figure 34. Asia Pacific Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn
Figure 35. Asia Pacific Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn
Figure 36. Asia Pacific Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn
Figure 37. Breakdown of Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue
Figure 38. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)
Figure 39. Asia Pacific Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn
Figure 40. Asia Pacific Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn
Figure 41. Breakdown of Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, % of Revenue
Figure 42. Asia Pacific Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%)
Figure 43. Asia Pacific Antibiotics Market: Oral Administration, 2019-2030, $ mn
Figure 44. Asia Pacific Antibiotics Market: Intravenous Administration, 2019-2030, $ mn
Figure 45. Asia Pacific Antibiotics Market: Other Administration Routes, 2019-2030, $ mn
Figure 46. Breakdown of Asia Pacific Antibiotics Market by Drug Type, 2019-2030, % of Revenue
Figure 47. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)
Figure 48. Asia Pacific Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn
Figure 49. Asia Pacific Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn
Figure 50. Breakdown of APAC Antibiotics Market by Country, 2019 and 2030, % of Revenue
Figure 51. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 52. Antibiotics Market in Japan, 2019-2030, $ bn
Figure 53. Antibiotics Market in China, 2019-2030, $ bn
Figure 54. Antibiotics Market in Australia, 2019-2030, $ bn
Figure 55. Antibiotics Market in India, 2019-2030, $ bn
Figure 56. Antibiotics Market in South Korea, 2019-2030, $ bn
Figure 57. Antibiotics Market in Rest of APAC, 2019-2030, $ bn
Figure 58. Growth Stage of Asia Pacific Antibiotics Industry over the Forecast Period


COMPANIES MENTIONED

Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.